{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:15:12Z","timestamp":1780103712560,"version":"3.54.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2025-0054_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Diabetic neuropathy results in chronic pain. Traditional treatments often offer limited relief, prompting the exploration of alternative therapies like Evening Primrose Oil (EPO). This study aimed to assess the efficacy of EPO in the treatment of painful diabetic neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2025-0054_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this interventional clinical trial, Patients were randomly assigned to three groups. Group A, consisted of 24 patients, received 1,000\u202fmg of EPO soft gel capsules every 12\u202fh. Group B, consisted of 21 patients, received 1,000\u202fmg of EPO soft gel capsules daily. Group C, also with 21 patients, was divided so that half of the patients received placebo capsules daily and the other half every 12\u202fh. After 4\u00a0weeks, patients returned, and questionnaires were completed. Statistical analysis of the data was conducted using SPSS version\u00a025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2025-0054_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Groups A and B showed significant reductions in\u00a0visual analog scale (VAS) pain scores, with Group A achieving the most improvement (mean pre-test: 5.96; post-test: 4.63). Analysis of covariance (ANCOVA) revealed significant differences in post-intervention scores (p&lt;0.001) for VAS and Neuropathy total symptom score-6 (NTSS-6), indicating effective interventions. Treatment A was more effective than Treatment B for reducing pain (VAS mean difference=\u00a0\u22120.52; p=0.044) and McGill Pain Questionnaire (MPQ) scores (mean difference=\u00a0\u22129.56; p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2025-0054_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EPO could serve as a valuable alternative therapy for managing painful diabetic neuropathy with fewer side effects than traditional treatments. Further research is warranted to validate these results and explore EPO treatment long-term efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2025-0054","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:39:25Z","timestamp":1747885165000},"page":"547-554","source":"Crossref","is-referenced-by-count":1,"title":["Effects of evening primrose oil on treating painful diabetic neuropathy: a randomized, double-blind, clinical trial"],"prefix":"10.1515","volume":"22","author":[{"given":"Ayub","family":"Gholami","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Branch , Islamic Azad University , Tehran , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Koulaeinejad","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Branch , Islamic Azad University , Tehran , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrali","family":"Rahimi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine , Kermanshah University of Medical Sciences , Kermanshah , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"2025121209150701231_j_jcim-2025-0054_ref_001","unstructured":"Dwivedi, M, Pandey, AR. Diabetes mellitus and its treatment: an overview. J\u00a0Adv Pharmacol 2020;1:48\u201358."},{"key":"2025121209150701231_j_jcim-2025-0054_ref_002","doi-asserted-by":"crossref","unstructured":"Saeedi, P, Petersohn, I, Salpea, P, Malanda, B, Karuranga, S, Unwin, N, et al.. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes Federation diabetes Atlas. Diabetes Res Clin Pract 2019;157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843.","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_003","doi-asserted-by":"crossref","unstructured":"Tomic, D, Shaw, JE, Magliano, DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol 2022;18:525\u201339. https:\/\/doi.org\/10.1038\/s41574-022-00690-7.","DOI":"10.1038\/s41574-022-00690-7"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_004","doi-asserted-by":"crossref","unstructured":"Hicks, CW, Selvin, E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diabetes Rep 2019;19:1\u20138. https:\/\/doi.org\/10.1007\/s11892-019-1212-8.","DOI":"10.1007\/s11892-019-1212-8"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_005","doi-asserted-by":"crossref","unstructured":"Yang, K, Wang, Y, Li, YW, Chen, YG, Xing, N, Lin, HB, et al.. Progress in the treatment of diabetic peripheral neuropathy. Biomed Pharmacother 2022;148:112717. https:\/\/doi.org\/10.1016\/j.biopha.2022.112717.","DOI":"10.1016\/j.biopha.2022.112717"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_006","doi-asserted-by":"crossref","unstructured":"R\u00f8ikjer, J, Ejskjaer, N. Diabetic peripheral neuropathy: diagnosis and treatment. Curr Drug Saf 2021;16:2\u201316. https:\/\/doi.org\/10.2174\/1574886315666200731173113.","DOI":"10.2174\/1574886315666200731173113"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_007","doi-asserted-by":"crossref","unstructured":"Ferini-Strambi, L. Neuropathic pain and sleep: a review. Pain and therapy 2017;6:19\u201323. https:\/\/doi.org\/10.1007\/s40122-017-0089-y.","DOI":"10.1007\/s40122-017-0089-y"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_008","doi-asserted-by":"crossref","unstructured":"H\u00f6ke, A, Sun, HS, Gordon, T, Zochodne, DW. Do denervated peripheral nerve trunks become ischemic? The impact of chronic denervation on vasa nervorum. Exp Neurol 2001;172:398\u2013406. https:\/\/doi.org\/10.1006\/exnr.2001.7808.","DOI":"10.1006\/exnr.2001.7808"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_009","doi-asserted-by":"crossref","unstructured":"Berciano, J. Inflammatory oedema of nerve trunks may be pathogenic in very early Guillain\u2013Barr\u00e9 syndrome. Acta Neurol Belg 2020;120:1061\u20135. https:\/\/doi.org\/10.1007\/s13760-020-01413-3.","DOI":"10.1007\/s13760-020-01413-3"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_010","unstructured":"Desouky, AA, Mahmmod, MA, Mohammad, MH, Sayed, \u0178Y. Effect of a nursing care bundle on severity of diabetic peripheral neuropathy. Assiut Sci Nurs J 2023;11:199\u2013211."},{"key":"2025121209150701231_j_jcim-2025-0054_ref_011","doi-asserted-by":"crossref","unstructured":"Sharifi, M, Nourani, N, Sanaie, S, Hamedeyazdan, S. The effect of Oenothera biennis (evening primrose) oil on inflammatory diseases: a systematic review of clinical trials. BMC Compl Med Ther 2024;24:89. https:\/\/doi.org\/10.1186\/s12906-024-04378-5.","DOI":"10.1186\/s12906-024-04378-5"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_012","doi-asserted-by":"crossref","unstructured":"Tahir, HE, Mahunu, GK, Mariod, AA, Xiaobo, Z, Afoakwah, NA. Biological activities of evening primrose oil. In: Multiple biological activities of unconventional seed oils. Academic Press; 2022:317\u201332 pp.","DOI":"10.1016\/B978-0-12-824135-6.00032-5"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_013","doi-asserted-by":"crossref","unstructured":"Azad, A, Pourtaheri, M, Darsareh, F, Heidari, S, Mehrnoush, V. Evening primrose oil for cervical ripening prior to labor induction in post-term pregnancies: a randomized controlled trial. Eur J Integr Med 2022;51:102123. https:\/\/doi.org\/10.1016\/j.eujim.2022.102123.","DOI":"10.1016\/j.eujim.2022.102123"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_014","doi-asserted-by":"crossref","unstructured":"Ogbera, AO, Ezeobi, E, Unachukwu, C, Oshinaike, O. Treatment of diabetes mellitus-associated neuropathy with vitamin E and Eve primrose. Indian J Endocrinol Metabol 2014;18:846\u20139. https:\/\/doi.org\/10.4103\/2230-8210.140270.","DOI":"10.4103\/2230-8210.140270"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_015","doi-asserted-by":"crossref","unstructured":"Yorek, MA. The potential role of fatty acids in treating diabetic neuropathy. Curr Diabetes Rep 2018;18:1\u20130. https:\/\/doi.org\/10.1007\/s11892-018-1046-9.","DOI":"10.1007\/s11892-018-1046-9"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_016","doi-asserted-by":"crossref","unstructured":"Nasrabadi, Z, Rakhshani, MH, Ebadi, H, Akbarzadeh, R. Comparison of the effect of gabapentin and evening primrose oil on peripheral neuropathy pain in patients with type 2 diabetes. Clin Med 2019;26:5\u201311. https:\/\/doi.org\/10.29252\/ajcm.26.1.5.","DOI":"10.29252\/ajcm.26.1.5"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_017","doi-asserted-by":"crossref","unstructured":"Ziegler, D, Ametov, A, Barinov, A, Dyck, PJ, Gurieva, I, Low, PA, et al.. Oral treatment with \u03b1-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365\u201370. https:\/\/doi.org\/10.2337\/dc06-1216.","DOI":"10.2337\/dc06-1216"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_018","doi-asserted-by":"crossref","unstructured":"Simon, D, Eng, PA, Borelli, S, K\u00e4gi, R, Zimmermann, C, Zahner, C, et al.. Gamma-linolenic acid levels correlate with clinical efficacy of evening primrose oil in patients with atopic dermatitis. Adv Ther 2014;31:180\u20138. https:\/\/doi.org\/10.1007\/s12325-014-0093-0.","DOI":"10.1007\/s12325-014-0093-0"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_019","doi-asserted-by":"crossref","unstructured":"Jamal, GA, Carmichael, H. The effect of \u03b3 linolenic acid on human diabetic peripheral neuropathy: a double blind placebo controlled trial. Diabet Med 1990;7:319\u201323. https:\/\/doi.org\/10.1111\/j.1464-5491.1990.tb01397.x.","DOI":"10.1111\/j.1464-5491.1990.tb01397.x"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_020","doi-asserted-by":"crossref","unstructured":"Timoszuk, M, Bielawska, K, Skrzydlewska, E. Evening primrose (Oenothera biennis) biological activity dependent on chemical composition. Antioxidants 2018;7:108. https:\/\/doi.org\/10.3390\/antiox7080108.","DOI":"10.3390\/antiox7080108"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_021","unstructured":"Aboutorabi, R, Saeedi, M. The effect of antiaging COQ10 plus on the treatment of diabetic neuropathy. Med J Mashhad Univ Med Sci 2014;57:793\u20138."},{"key":"2025121209150701231_j_jcim-2025-0054_ref_022","doi-asserted-by":"crossref","unstructured":"Farag, MA, Reda, A, Nabil, M, Elimam, DM, Zayed, A. Evening primrose oil: a comprehensive review of its bioactives, extraction, analysis, oil quality, therapeutic merits, and safety. Food Funct 2023;14:8049\u201370. https:\/\/doi.org\/10.1039\/d3fo01949g.","DOI":"10.1039\/D3FO01949G"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_023","doi-asserted-by":"crossref","unstructured":"Fisher, AS, Lanigan, MT, Upton, N, Lione, LA. Preclinical neuropathic pain assessment; the importance of translatability and bidirectional research. Front Pharmacol 2021;11:614990. https:\/\/doi.org\/10.3389\/fphar.2020.614990.","DOI":"10.3389\/fphar.2020.614990"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_024","doi-asserted-by":"crossref","unstructured":"Omran, OM. Histopathological study of evening primrose oil effects on experimental diabetic neuropathy. Ultrastruct Pathol 2012;36:222\u20137. https:\/\/doi.org\/10.3109\/01913123.2012.662268.","DOI":"10.3109\/01913123.2012.662268"},{"key":"2025121209150701231_j_jcim-2025-0054_ref_025","doi-asserted-by":"crossref","unstructured":"Horrobin, DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997;46:S90\u20133. https:\/\/doi.org\/10.2337\/diab.46.2.s90.","DOI":"10.2337\/diab.46.2.S90"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2025-0054\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2025-0054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:54:03Z","timestamp":1765540443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2025-0054\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2025,9,25]]}},"alternative-id":["10.1515\/jcim-2025-0054"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2025-0054","relation":{},"ISSN":["1553-3840"],"issn-type":[{"value":"1553-3840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}